04:00:55 PM

CFRX Stock News

CFRX - ContraFect Corp

09/19/23 8:30 AM

Nasdaq : CFRX

conferenceslow float

ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development

ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Jane Ambler, Ph.D., the Company’s

RHEA-AI

negative

09/18/23 7:30 AM

Nasdaq : CFRX

clinical triallow float

ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370

RHEA-AI

negative

08/28/23 8:00 AM

Nasdaq : CFRX

conferenceslow float

ContraFect to Present at the World Anti-Microbial Resistance Congress 2023

RHEA-AI

negative

08/14/23 8:30 AM

Nasdaq : CFRX

earningslow float

ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update

RHEA-AI

negative

06/27/23 8:30 AM

Nasdaq : CFRX

low float

ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million

RHEA-AI

neutral

06/20/23 8:59 AM

Nasdaq : CFRX

low float

ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens

RHEA-AI

negative

06/08/23 4:01 PM

Nasdaq : CFRX

conferenceslow float

ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023

RHEA-AI

negative

05/15/23 8:00 AM

Nasdaq : CFRX

earningslow float

ContraFect Reports First Quarter 2023 Financial Results and Provides Business Update

RHEA-AI

negative

04/26/23 9:00 AM

Nasdaq : CFRX

clinical triallow float

ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee

RHEA-AI

neutral

04/20/23 8:30 AM

Nasdaq : CFRX

low float

ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative Pathogens

RHEA-AI

very negative

1 2 3 4 5 6 7 Next

CFRX Data

IndustryPharmaceutical Preparation Manufacturing
Websitehttps://www.contrafect.com/
Security nameContraFect Corp
SectorManufacturing
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
CountryUS

About ContraFect Corp

we are a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, particularly those treated in hospital-based settings. due to drug-resistant and newly-emerging pathogens, infections in the hospital are already the fourth leading cause of death in the united states, following heart disease, cancer and stroke. we address multi-drug resistant infections using our therapeutic products from our lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. our strategy is to use our first in class therapies to achieve a leadership position in the treatment of life-threatening infectious diseases, including drug-resistant pathogens. we plan to pursue commercialization of therapeutic products through discovery, acquisition and development of protein and antibody products. our novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills ba